Skip to content

electroCore, Inc. ECOR Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Apple logo
AppleAAPL
AbbVie logo
AbbVieABBV
Neuropace, Inc. logo
Neuropace, Inc.NPCE
ClearPoint Neuro logo
ClearPoint NeuroCLPT
Avanos Medical logo
Avanos MedicalAVNS
Globus Medical logo
Globus MedicalGMED

Other financials

Income statement

See full
Revenue$9.6M+42.6%
Gross profit$8.4M+46.6%
Operating income-$5.3M-39.1%
Net income-$5.3M-36.7%
EPS (diluted)-$0.59-25.5%

Balance sheet

See full
Cash & equivalents$4.9M+20.5%
Total debt$9.5M+127%
Total equity-$5.7M-230%
Total assets$15.5M-3.5%

Cash flow

See full
Operating cash flow-$3.0M+30.9%
CapEx$2.0K-94.6%
Free cash flow-$3.0M+31.5%

Valuation

See full
Market cap$71.67M+81.6%
Enterprise value$76.31M+90.2%
P/S2.1×+0.6×

Profitability

See full
Gross margin87.2%+2.0pp
Operating margin-42%-3.3pp
Net margin-44.1%-2.0pp
FCF margin-19.7%

Returns & leverage

See full
Return on equity-210.6%+125pp
Debt / equity3.8×+3.5×
Current ratio-0.5×

Where this comes from

Reported directly by electroCore, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: electroCore, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about electroCore, Inc.'s common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is electroCore, Inc.'s common stock, shares authorized (in shares)?
electroCore, Inc. (ECOR) reported common stock, shares authorized (in shares) of $500M in Q1 2026.
How has electroCore, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
electroCore, Inc.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $500M to $500M.
What is the long-term trend for electroCore, Inc.'s common stock, shares authorized (in shares)?
Over 4 years (2021 to 2025), electroCore, Inc.'s common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $500M to $500M.